Alembic Pharma Q1 Review - Numbers Dwindle; U.S. Traction Key For Margins, Return Ratios: ICICI Direct


BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Alembic Pharmaceuticals Ltd.’s revenues declined 5% YoY to Rs 1262 crore. Domestic formulations were flat YoY at Rs 480 crore while domestic business grew 20% YoY adjusting for Covid sales in Q1 FY22.

U.S. generics was also flat YoY at Rs 367 crore, mainly due to price erosion across the portfolio and high stocking in Q4 FY22. International formulations sales de-grew 8% YoY at Rs 182 crore while active pharma ingredients also declined 16% YoY to Rs 233 crore mainly impacted by lower volumes.

Ebitda margins declined 1647 basis points YoY to 1.2% mainly due to higher other expenditure (Aleor Dermaceuticals Ltd.’s recurring research and development expenses of Rs 100 crore).

Alembic Pharma posted loss of Rs 66 crore versus adjusted profit after tax of Rs 164 crore in Q1 FY22. Adjusted for Aleor’s impact, profit after tax was at Rs 36 crore.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.





Image and article originally from www.bqprime.com. Read the original article here.